{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:47:08Z","timestamp":1791100028084,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,7,15]],"date-time":"2004-07-15T00:00:00Z","timestamp":1089849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Objective.\u2002<\/jats:bold> In amyloid A (AA) amyloidosis the receptor for advanced glycation end products is a target for the circulating amyloid precursor protein (SAA) resulting in upregulation of the proinflammatory cytokine pathway. Besides inducing hepatic SAA synthesis the interleukin\u20101 cytokine family is involved in the regulation of haematopoiesis. We therefore studied the relationship between the circulating levels of interleukin\u20101<jats:italic>\u03b2<\/jats:italic> (IL\u20101<jats:italic>\u03b2<\/jats:italic>) and interleukin\u201018 (IL\u201018), a new member of the IL\u20101 complex, as well as polymorphisms within the IL\u20101 cluster with the occurrence of anaemia in patients with AA amyloidosis.<\/jats:p><jats:p><jats:bold>Design, setting and subjects.\u2002<\/jats:bold> The study included 54 adult patients with biopsy\u2010proven reactive amyloidosis allocated into three groups on the basis of haemoglobin (Hb) level: group I included all patients with Hb\u2003&lt;\u2003110\u2003g\u2003L<jats:sup>\u22121<\/jats:sup> (<jats:italic>n<\/jats:italic>\u2003=\u200316); group II patients (Hb\u2003&gt;\u2003110\u2003g\u2003L<jats:sup>\u22121<\/jats:sup>, <jats:italic>n<\/jats:italic>\u2003=\u200316) were selected to match group I patients with respect to sex, age, underlying disease (seropositive, erosive rheumatoid arthritis) and renal function; and group III patients (<jats:italic>n<\/jats:italic>\u2003=\u200338) represented all patients (unselected) with Hb\u2003\u2265\u2003110\u2003g\u2003L<jats:sup>\u22121<\/jats:sup>. Gene polymorphisms were studied by polymerase chain reaction restriction length assay and included the base exchange at position\u2010889 of the IL\u20101<jats:italic>\u03b1<\/jats:italic> gene, the polymorphic region at position\u2010511 and the polymorphic locus at exon 5, position +3954 of the IL\u20101<jats:italic>\u03b2<\/jats:italic> gene, as well as the IL\u20101 receptor antagonist (IL\u20101Ra) exon 2 polymorphism caused by the 86\u2010bp tandem repeats. Plasma IL\u20101<jats:italic>\u03b2<\/jats:italic>, IL\u20101<jats:italic>\u03b1<\/jats:italic>, IL\u201018, IL\u20101 Ra, SAA, ferritin, soluble transferrin receptor and erythropoietin levels were studied by enzyme immunoassays.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> Circulating IL\u2010<jats:italic>\u03b2<\/jats:italic> and IL\u201018 were significantly raised in the anaemic patients with AA amyloidosis when compared with group II patients (matched, Hb\u2003&gt;\u2003110\u2003g\u2003L<jats:sup>\u22121<\/jats:sup>) as well as group III patients (nonmatched, Hb\u2003\u2265\u2003110\u2003g\u2003L<jats:sup>\u22121<\/jats:sup>). A significant inverse relationship was found between IL\u20101<jats:italic>\u03b2<\/jats:italic> and haemoglobin levels, as well as between IL\u201018 and haemoglobin levels. The frequency of allele 2 (T) of the IL\u20101<jats:italic>\u03b2<\/jats:italic>\u2010511 promoter gene was significantly increased and that of allele 1 (C) decreased in anaemic amyloid patients (group I) when compared with group II and III patients. Circulating IL\u20101<jats:italic>\u03b2<\/jats:italic> levels tended to be higher amongst the IL\u20101<jats:italic>\u03b2<\/jats:italic>\u2010511 allele 2 carriers than amongst the noncarriers, as well as amongst the anaemic amyloid patients filling all criteria of anaemia of chronic disease.<\/jats:p><jats:p><jats:bold>Conclusion.\u2002<\/jats:bold> The occurrence of anaemia in patients with AA amyloidosis is associated with allele 2 (T) of the IL\u20101<jats:italic>\u03b2<\/jats:italic>\u2010511 promoter gene and elevated levels of circulating IL\u20101<jats:italic>\u03b2<\/jats:italic> and IL\u201018. In AA amyloidosis the raised cytokine levels may generate a vicious cycle leading to accelerated amyloidogenesis, suppression of erythropoiesis and aggravation of the underlying inflammatory disorder.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2004.01353.x","type":"journal-article","created":{"date-parts":[[2004,7,15]],"date-time":"2004-07-15T13:25:45Z","timestamp":1089897945000},"page":"145-152","source":"Crossref","is-referenced-by-count":18,"title":["Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin\u20101\u03b2\u2010511 promoter gene and raised levels of interleukin\u20101\u03b2 and interleukin\u201018"],"prefix":"10.1111","volume":"256","author":[{"given":"C. P. J.","family":"Maury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liljestr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Laiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tiitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kaarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hurme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,15]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079469"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M213298200"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)00465-5"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00927-6"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/76216"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780116"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.10.5296"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm890"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.12.972"},{"key":"e_1_2_11_12_2","first-page":"159","article-title":"Mechanisms of anaemia and cachexia of chronic disease: evidence for a role of interleukin\u20101\u03b2 and tumour necrosis factor\u2010\u03b1","volume":"2","author":"Maury CPJ","year":"1991","journal-title":"Eur J Int Med"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00154.x"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4736"},{"key":"e_1_2_11_15_2","first-page":"116","article-title":"Recent developments in anemia of chronic disease","volume":"2","author":"Means RT","year":"2003","journal-title":"Curr Hematol Rev"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_11_17_2","first-page":"600","article-title":"Interleukin\u20101\u03b2, interleukin\u20101\u2010receptor antagonist and interleukin\u20106 plasma levels and cytokine polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters","volume":"85","author":"Hulkkonen J","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541320"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1016::AID-ANR9>3.0.CO;2-3"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1992.tb01480.x"},{"key":"e_1_2_11_22_2","first-page":"251","article-title":"A rare allele combination of the interleukin\u20101 gene complex is associated with high interleukin\u20101\u03b2 plasma levels in healthy individuals","volume":"11","author":"Hulkkonen J","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_11_23_2","first-page":"195","article-title":"Presence of the IL1RA allele 2 (IL1RN*2) is associated with enhanced IL\u20101\u03b2 production in vitro","volume":"47","author":"Santtila S","year":"1998","journal-title":"Scand J Rheumatol"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199906)42:6<1093::AID-ANR5>3.0.CO;2-P"},{"key":"e_1_2_11_25_2","first-page":"212","article-title":"Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF\u2010\u03b1, IL\u20101\u03b2, and IL\u20101Ra genes","volume":"29","author":"Cvetkovic JT","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.9.1621"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90001-V"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0136"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.555"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.12.2328.2328"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2101"},{"key":"e_1_2_11_32_2","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1016\/S0021-9258(18)99230-6","article-title":"receptor antagonist binds to the 80\u2010kDa IL\u20101 receptor but does not initiate IL\u20101 signal transduction","volume":"266","author":"Dripps DJ","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12520-2"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2660(01)42023-2"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/35042049"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7317"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"e_1_2_11_39_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby P.","year":"2000","journal-title":"Nature"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2004.01353.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2004.01353.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:32:18Z","timestamp":1697149938000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2004.01353.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,15]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1365-2796.2004.01353.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01353.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,15]]}}}